ALS Studies and Lessons Learned From COVID-19
The disruptions caused by COVID-19 have complicated both the initiation and execution of clinical trials involving therapies targeting amyotrophic lateral sclerosis (ALS). Read our experts’ perspectives on how to flex during this global pandemic.
Your form has been successfully submitted! Click the button below to access.READ MORE